Joint Pain Injections Market size was over USD 6 billion in 2024 and is estimated to reach USD 20.3 billion by the end of 2037, expanding at a CAGR of 10.7% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of joint pain injections is assessed at USD 6.6 billion.
A key driver of the market growth is the aging population, which is more susceptible to chronic joint conditions, particularly in the developed and developing regions. According to the 2019 World Population Prospects, 1 in 6 people in the world will be over age 65, which is a big leap from 1 in 11 people in 2019. The rising incidence of obesity and sedentary lifestyles is further contributing to the growing need for joint pain management solutions worldwide.
As per the National Safety Council, injuries increased by 20% in 2021 from 2020, 12% in 2022, and now 2% in 2023. These rising numbers of physical injuries are also boosting the market growth. Disorders such as osteoarthritis, and other degenerative joint diseases are driving the market growth further. According to the Radiological Society of North America (RSNA) 2022, osteoarthritis affects 32.5 million adults in the U.S. 43% of people suffering from the disease are 65 or older and 88% of people with OA are 45 or older, and 62% of individuals with OA are women. In 2023, 3.7 million people were treated in emergency departments for injuries involving sports and recreational equipment. These factors are projected to significantly boost the joint pain injections market growth during the forecast period.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
10.7% |
|
Base Year Market Size (2024) |
USD 6 billion |
|
Forecast Year Market Size (2037) |
USD 20.3 billion |
|
Regional Scope |
|
Product (Corticosteroid Injections, Hyaluronic Acid Injections, Platelet Rich Plasma Injections, Others)
Based on product, hyaluronic acid injections segment is set to account for joint pain injections market share of more than 68.9% by the end of 2037. This is majorly due to their effectiveness in providing long-term relief in the knee joint. In January 2018, OrthogenRx, Inc. launched TriVisc (sodium hyaluronate) treating osteoarthritic (OA) knee pain for people who fail to receive adequate relief from painkillers and physical therapies. Increasing regulatory approvals from governments of various regions, growing awareness of its benefits among the patients, and a shift towards viscosupplementation over corticosteroids due to fewer side effects further boost their demand.
Joint Type (Knee, Hip, Hand & Wrist, Others)
Based on joint type, the knee segment is anticipated to register steady growth during the forecast period in the joint pain injections market. The segment is driven by a high prevalence of osteoarthritis, increased physical activity levels, and rising obesity rates. In September 2024, Sun Pharma and Moebius Medical Limited received U.S. FDA Fast Track designation (FTD) approval for MM-II for treating osteoarthritis knee pain. Data from a randomized, controlled, Phase 2b study showcased that a single intra-articular injection of 3mL offered better pain relief in comparison to a placebo for up to 26 weeks. Advancements in injection therapies, including hyaluronic acid and platelet-rich plasma, provide targeted relief, driving their adoption for knee treatments.
Our in-depth analysis of the global market includes the following segments:
|
Product |
|
|
Joint Type |
|
|
Distribution Channel |
|
APAC Market Statistics
APAC joint pain injections market is expanding rapidly driven by the increasing elderly population and rising cases of osteoarthritis and rheumatoid arthritis across the region. Furthermore, rising awareness of non-surgical treatments and the adoption of advanced therapies are boosting the market growth in India. Lifestyle changes, including sedentary habits and higher obesity rates, contribute to the growing need for joint pain management in the country.
India market is expanding due to the increasing burden of arthritis and related disorders, coupled with rising healthcare investments. As per Statista 2024, the number of arthritis cases in senior citizens all over India is forecasted to reach 96.7 million by 2050. Additionally, the demand for cost-effective treatments and the presence of a large patient population contribute to the market’s upward trajectory.
China joint pain injections market stands out in the APAC region driven by increased adoption of joint injections for chronic pain management, particularly in large urban centers where healthcare access is more robust. Government policies aimed at improving elderly care are supporting market growth. Moreover, the expansion of domestic pharmaceutical companies and partnerships with global players is enhancing the availability and quality of joint pain treatments.
North America Market Analysis
North America joint pain injections market is poised for significant growth, driven by the increasing prevalence of musculoskeletal disorders and the rising geriatric population. Moreover, according to Statista 2024, around 29.1% of women and 21.4% of men in the U.S. suffered from arthritis in 2023. With a strong healthcare infrastructure and a high adoption rate of advanced medical technologies, North America is the leading region in this market.
The U.S. market is a significant contributor to North America’s leadership. Key players are driving innovation by developing advanced treatments and expanding their product portfolios. For instance, in April 2022, Dr. Reddy’s Laboratories Ltd. launched Methylprednisolone Sodium Succinate for Injection, USP, the generic equivalent of SOLU-MEDROL in the U.S. market approved by the U.S. FDA. The U.S. market is further fueled by rising healthcare expenditures and a large patient pool.
Canada joint pain injections market is experiencing moderate growth due to a well-established healthcare system and rising awareness of non-surgical pain management options. The Canada market is supported by government healthcare initiatives aimed at improving the quality of life for aging populations. Like the U.S., Canada is witnessing increased demand for hyaluronic acid and platelet-rich plasma (PRP) injections for knee and hip treatments.
Companies in the joint pain injections market are leveraging mergers and acquisitions to expand their portfolios. Geographical expansions and product launches are two more growth strategies adopted by these players in the market. For instance, in August 2021, Seikagaku Corporation launched HyLink, through TCM Biotech International Corp., in Taiwan. HyLink is an intra-articular single-injection viscosupplement, aimed at treating knee osteoarthritis. Such developments are anticipated to lead to steady industry expansions for these companies and boost market growth significantly. Here’s a list of the prominent players in the joint pain injections market:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?